| MeSH term | MeSH ID | Detail |
|---|---|---|
| Pseudomyxoma Peritonei | D011553 | 1 associated lipids |
| Eye Infections | D015817 | 1 associated lipids |
| Upper Extremity Deep Vein Thrombosis | D056824 | 1 associated lipids |
| Gastritis, Hypertrophic | D005758 | 1 associated lipids |
| Buruli Ulcer | D054312 | 1 associated lipids |
| Tuberculosis, Spinal | D014399 | 1 associated lipids |
| Hypoproteinemia | D007019 | 1 associated lipids |
| Myxoma | D009232 | 1 associated lipids |
| Epilepsy, Partial, Motor | D020938 | 1 associated lipids |
| Cutaneous Fistula | D017577 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Fischbach L and Evans EL | Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17635369 |
| Labenz J et al. | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730252 |
| Thijs JC et al. | Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:8186339 |
| Gisbert JP et al. | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882246 |
| al-Assi MT et al. | Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986970 |
| Neri M et al. | Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986974 |
| Boixeda D et al. | Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:12182745 |
| Bruley Des Varannes S et al. | There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472320 |
| Adachi K et al. | Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472321 |
| Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
| Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11472323 |
| Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
| Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
| Gschwantler M et al. | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468682 |
| Paré P et al. | Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468683 |
| Sung JJ et al. | One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10468684 |
| Chiba N et al. | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:14984382 |
| Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
| Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
| Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
| Laine L | Review article: esomeprazole in the treatment of Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:12047270 |
| Molina-Infante J et al. | Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. | 2015 | Aliment. Pharmacol. Ther. | pmid:25776067 |
| Sung JJ et al. | One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726384 |
| Pazzi P et al. | Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726385 |
| Harris AW et al. | Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group. | 1998 | Aliment. Pharmacol. Ther. | pmid:9726387 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Vakil N et al. | Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. | 2008 | Aliment. Pharmacol. Ther. | pmid:18774949 |
| Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
| Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
| Wong BC et al. | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736727 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
| Sengupta S et al. | Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803607 |
| Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
| Rinaldi V et al. | The management of failed dual or triple therapy for Helicobacter pylori eradication. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354202 |
| Breuer T et al. | Clarithromycin, amoxycillin and H2-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354204 |
| Wurzer H et al. | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354205 |
| Harris A | H. pylori eradication by LAC. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354216 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Gisbert JP et al. | Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. | 2012 | Aliment. Pharmacol. Ther. | pmid:22372560 |
| Harris AW et al. | Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971302 |
| Moshkowitz M et al. | One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971304 |
| Laine L et al. | Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971306 |
| Graham DY et al. | Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755836 |